Published by Josh White on 1st June 2026
(Sharecast News) - Avacta said on Monday that updated clinical data for its AVA6000 cancer therapy showed encouraging early efficacy signals in patients with salivary gland cancers, alongside a continuing favourable safety profile.
URL: http://www.digitallook.com/dl/news/story/35969418/...